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Objective: Early severe graft dysfunction, as manifested by hypoxia and 
pulmonary hypertension, occurs in 10% to 20% of lung transplant recipients. 
We retrospectively investigated whether inhaled nitric oxide would reduce 
human lung allograft dysfunction by comparing postoperative hemodynamic 
data, gas exchange, and outcome in lung transplant recipients with early graft 
dysfunction treated with or without nitric oxide. Method: Among 243 adult lung 
transplant procedures, there were 32 patients (13.2%) in whom immediate 
severe allograft dysfunction developed (arterial oxygen tension/inspired oxygen 
concentration ratio < 150). Group 1 (n = 17) included patients who underwent 
transplantation before nitric oxide became available in our center and were 
treated conventionally. Group 2 (n = 15) included those treated with nitric 
oxide as soon as severe allograft dysfunction was diagnosed. Duration of nitric 
oxide therapy (20 to 60 ppm) was 15 to 217 hours (average 84 hours). Results: 
In group 2, nitric oxide lowered mean pulmonary artery pressure from 30 -+ 2 
to 26 l+ 2 mm Hg (p < 0.05), improved the ratio of arterial oxygen tension to 
inspired oxygen fraction from 88 -+ 10 to 153 -+ 30 (p < 0.05) within 1 hour, 
and caused a sustained improvement in these parameters during extended 
therapy. Mean arterial pressure and cardiac index were unchanged uring 
nitric oxide therapy. Transient methemoglobinemia (>6%) developed in two 
patients. However, no complications were associated with nitric oxide use. 
Duration of mechanical ventilation was 17 +- 5 days in group I and 12 -+ 3 days 
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in group 2. Four patients had airway complications in group 1, whereas no 
airway complication was encountered in group 2. Mortality was 24% (4/17) 
in group 1 and 7% (1/15) in group 2. Conclusion: Nitric oxide improves 
oxygenation and decreases pulmonary artery pressure without systemic 
circulatory elfects in patients with severe allograft dysfunction. Further- 
more, in these patients, nitric oxide may shorten postoperative mechanical 
ventilation time and reduce airway complications and mortality. (J Thorac 
Cardiovasc Surg 1996;111:913-9) 
D espite improved preservation methods and peri- operative management, severe allograft dysfunc- 
tion occurs in 10% to 20% of lung transplant 
recipients.i, 2 Its associated severe hypoxia, pulmo- 
nary hypertension, and lung edema complicate post- 
operative management. Nitric oxide was reported to 
be an important endothelium-derived r laxing fac- 
tor in 1987. 3 Rossaint and colleagues 4 reported in 
1993 that extended treatment with inhaled nitric 
oxide for patients with severe adult respiratory 
distress syndrome reduces the pulmonary artery 
pressure without producing systemic vasodilatation 
and increases arterial oxygenation by improving 
ventilation-perfusion matching. We 5 recently tested 
the effect of short periods of nitric oxide inhalation 
on hemodynamics and arterial oxygenation in pa- 
tients after bilateral lung transplantation. Nitric 
oxide dramatically improved the arterial oxygen 
tension/inspired oxygen fraction (Pao2/Fio2) ratio 
and lowered the mean pulmonary artery pressure in 
patients with impaired oxygenation. We 6 recently 
demonstrated that nitric oxide markedly improved 
posttransplantation gas exchange in canine lung 
allografts tored for 18 hours. The purpose of this 
report was to compare the effects of inhaled nitric 
oxide with conventional therapy in a group of lung 
transplant recipients with severe allograft dysfunc- 
tion. 
Patients and methods 
Between September 1988 and December 1994, 243 
consecutive single (n = 111) and bilateral sequential 
single (n = 132) lung transplants were performed at 
Barnes Hospital. En bloc double lung transplants (n = 8) 
performed in our early experience were not included in 
this study. Thirty-two patients (13.2%) had immediate 
severe allograft dysfunction, as manifested by a Pao2/Fio2 
ratio less than 150. These 32 patients were divided into 
two groups. Group 1 (n = 17) included patients having 
lung transplantation before January 1993 (when inhaled 
nitric oxide became available in our institution) and 
treated conventionally. Group 2 (n = 15) included those 
patients having lung transplantation after February 1993 
and treated with inhaled nitric oxide as soon as severe 
allograft dysfunction was diagnosed. These two groups 
were compared in regard to requirement for extracorpo- 
real membrane oxygenation (ECMO), days requiring me- 
chanical ventilation, airway complications, and mortality. 
In group 2, the effect of inhaled nitric oxide was evaluated 
by the changes of systemic and pulmonary hemodynamics 
and arterial blood gases measured before and during 
nitric oxide treatment. 
Donor lungs were harvested by the technique we 7 have 
previously described. All donors were pretreated with 
systemic heparin and the pulmonary artery bed was 
flushed with modified Euro-Collins olution after prosta- 
glandin E 1 (500/xg) administration. All transplant opera- 
tions were performed by means of previously described 
techniques. ~ Cardiopulmonary bypass was used in all 
patients with pulmonary hypertension and in other pa- 
tients as dictated by inadequate gas exchange or hemody- 
namics during transplantation. 9 
Routine clinical monitoring of the patients included a 
radial arterial line and a 7.5F Swan-Ganz catheter (Baxter 
Healthcare Corp., Irvine, Calif.) positioned into the pul- 
monary artery through the internal jugular vein. Systemic, 
pulmonary artery, pulmonary wedge, and central venous 
pressures were recorded. Cardiac output was determined 
by the thermodilution method. 
Postoperative sedation included intravenous fentanyl 
citrate and midazolam. Vecuronium bromide was given 
when indicated. Inotropic support, vasodilators, and di- 
uretics were used as necessary tomaximize hemodynamic 
stability and graft function. Prostaglandin E 1 (0.01 to 0.03 
/zg/kg per minute) was administered routinely from 1989 
unless significant hypotension was encountered. All pa- 
tients received mechanical ventilation in the volume- 
controlled mode with the application of positive end- 
expiratory pressure (5 to 15 cm H20 ). Ventilator settings 
were adjusted to provide adequate oxygenation as mea- 
sured by Pao 2 and adequate ventilation as measured by 
arterial pH and carbon dioxide tension. Standard immu- 
nosuppression consisted of cyclosporine, azathioprine, 
steroid, and antilymphocyte antibody as reported previ- 
ously. 1° 
Nitric oxide was supplied from Scott Specialty Gases 
(Plumsteadville, Pa.) in cylinders containing nitric oxide in 
nitrogen in a concentration of 2200 ppm. The delivery 
system consisted of a reducing valve and a flowmeter. The 
nitric oxide gas mixture (1/8 to 1/4 L/min) was delivered 
into the inspiratory port of the ventilator. The concentra- 
tion of nitric oxide was continuously measured from a 
sampling line at the Y connector attached to the endotra- 
cheal tube; a chemiluminescence device (model 42A, 
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Table I. Characteristics of patients 
Group 1 
(n = 17): Group 2 
without (n = 15): 
NO with NO Probability 
Recipient age (yr) 40.7 ± 3.5 44.3 ± 2.8 NS 
Recipient sex (M/F) 4/13 5/9 NS 
Donor age (yr) 22.3 ± 1.5 25.6 ± 2.8 NS 
Donor Pao2 (mm Hg) 455 _+ 16 452 ± 16 NS 
Diagnosis NS 
Obstructive 4 4 
Restrictive 4 3 
Septic 5 3 
PVD 4 5 
Procedure NS 
Single 8 3 
Bilateral 9 12 
Total ischemic time 380 _+ 26 369 ± 24 NS 
(min) 
CPB (yes/no) 8/9 8/7 NS 
Initial Pao2 (mm Hg) 80.8 ± 7.4 82.6 ± 8.1 NS 
NO, nitric oxide; PVD, primary pulmonary hypertension and Eisen- 
menger's syndrome; CPB, cardiopulmonary b pass; NS, not significant. 
Donor Pao2 and initial Pao2 were measured with Fio2 100%. 
Thermoenvironmental Instruments, Franklin, Mass.) that 
was calibrated before each use with a calibration gas of 
known 25 _+ 1 ppm nitric oxide in nitrogen (Scott Specialty 
Gases) was used to obtain these measurements. The flow 
was adjusted according to the concentration measured by 
the analyzer. The starting dose of inhaled nitric oxide was 
40 to 60 ppm and the gas was gradually weaned to 20 ppm. 
It was continued until its cessation did not cause deteri- 
oration in oxygenation or pulmonary artery pressure. 
Methemoglobin levels were measured every 2 to 6 hours 
with a Co-Oximeter (model 2500, Ciba-Corning, Med- 
field, Mass.) by means of a multiple wave-length spectro- 
photometric method. When methemoglobinemia (>6%) 
was noticed, 1 gm of ascorbic acid was given intravenously 
and the dose of nitric oxide was reduced. 
Informed consent was obtained from all patients for 
nitric oxide administration and the protocol for nitric 
oxide use was approved by the Human Studies Committee 
of Washington University. 
All data are presented as the mean -- the standard error 
of the mean. Significance was sought between the two 
groups with use of a )(2 test for nonparametric data and 
Student's t test for parametric data. Repeated-measures 
analysis of variance was used to test the effect of nitric 
oxide on systemic and pulmonary hemodynamics and also 
on arterial blood gas analysis. Statistical significance was 
determined at a p value of 0.05. 
Results 
Demographic results (Table I). Recipient age, re- 
cipient sex, donor age, donor Pao2, procedure, total 
ischemic time, use of cardiopulmonary bypass dur- 
ing transplant procedures, and initial Pao 2 (Fio 2 = 
Table II. Comparison of outcome between the two 
groups 
Group 1 (n = 17) Group 2 (n = 15) 
without NO with NO 
ECMO 3/17 = 18% 3/15 = 20% 
Days ventilated 17 ± 5 12 ± 3 
Airway complication 4/17 = 24% 0/15 = 0% 
Hospital mortality 4/17 = 24% 1/15 = 7% 
NO, Nitric oxide; ECMO, extracorporeal membrane oxygenation. 
1.0) after reperfusion were not significantly different 
between the two groups. 
Comparison of outcome between the two groups. 
(Table II). Three patients in each group required 
ECMO. Five of them, all three patients in group 1 
and two patients in group 2, required ECMO imme- 
diately after transplantation because they could not 
be weaned from cardiopulmonary bypass owing to 
severe allograft dysfunction. In one group 2 patient 
ECMO was begun 24 hours after transplantation 
because of progressive allograft dysfunction despite 
nitric oxide treatment. Two patients requiring 
ECMO in each group ultimately recovered and one 
patient requiring ECMO in each group died of 
severe allograft dysfunction. 
Duration of mechanical ventilation required was 
17 2 5 days in group 1 and 12 2 3 days in group 2. 
Four patients in group 1 had airway complica- 
tions. Early fatal bronchial dehiscence occurred in 
two patients, one of whom underwent retransplan- 
tation without success, and late bronchial stenosis 
occurred in two patients. In contrast, no airway 
complication was encountered in group 2. 
Hospital mortality was four of 17 (24%) in group 
1 and one of 15 (7%) in group 2. Causes of death in 
group 1 were airway dehiscence in two patients, 
severe allograft dysfunction in one, and sepsis in one 
patient. One patient in group 2 died of severe 
allograft dysfunction. 
Requirement of ECMO, duration of mechanical 
ventilation, airway complication, and hospital mor- 
tality did not reach statistical significance between 
the two groups. 
Effect of inhaled nitric oxide. Nitric oxide treat- 
ment was initiated in the operating room in four 
patients and on arrival at the intensive care unit in 
five patients. In the remaining six patients, nitric 
oxide was initiated 1 to 10 hours after they arrived in 
the intensive care unit because of progressive al- 
lograft dysfunction. Duration of nitric oxide therapy 
was 15 to 217 hours (average 84 hours). 
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Fig. 1. Pao2/Fio 2 ratio before (BL, baseline) and after 
nitric oxide treatment. Statistical nalysis was performed 
on the data obtained uring the first 8 hours because of 
the different durations of nitric oxide (NO) therapy in 
each case. *p < 0.05, **p < 0.01 (versus baseline). 
The effect of nitric oxide on hemodynamics and 
arterial blood gases was evaluated by comparing the 
data obtained uring nitric oxide therapy and those 
obtained immediately before nitric oxide therapy 
was initiated (baseline value). Data were obtained 
from 13 patients treated with inhaled nitric oxide, 
excluding two patients who required ECMO imme- 
diately after transplantation. Because the duration 
of nitric oxide therapy was different in each case, 
statistical analysis was performed on the data ob- 
tained during the first 8 hours (Table III). Nitric 
oxide administration resulted in rapid improvement 
of arterial oxygenation and pulmonary artery pres- 
sure without affecting systemic pressure or cardiac 
index and caused a sustained improvement in these 
parameters during extended therapy (Figs. 1 and 2). 
Transient methemoglobinemia (>6%) developed 
in two patients, 10.5% after 24 hours and 6.7% after 
8 hours, respectively, on a nitric oxide concentration 
of 40 ppm. Both patients were successfully treated 
with ascorbic acid administration a d reduction of 
nitric oxide dose. No complications were associated 
with nitric oxide administration. 
Discussion 
Early severe allograft dysfunction, as manifested 
by allograft edema, pulmonary hypertension, and 
decreased arterial oxygenation, develops in 10% to 
20% of lung transplant recipients. I' 2 This dysfunc- 
tion has been known as pulmonary reimplantation 
response. 11Ischemia-reperfusion njury is thought 
to be the major cause of this phenomena. I2 A 
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Fig. 2. Mean pulmonary artery (PA) pressure before 
(BL, baseline) and after nitric oxide (NO) treatment. 
Statistical nalysis was performed on the data obtained 
during the first 8 hours because of the different durations 
of nitric oxide therapy in each case. *p < 0.05 (versus 
baseline). 
number of strategies have been developed in an 
attempt o reduce early allograft dysfunction, for 
example, use of oxygen-derived radical scavengers, x3 
pentoxifyllin@ 4 and prostaglandin El. 15 However, 
13% of deaths occurred within 90 days after trans- 
plantation and were still attributable to severe al- 
lograft dysfunction at the moment according to the 
St. Louis International Lung Transplant Registry 
(Pohl MS, personal communication). 
Endothelial dysfunction may play a central role in 
pulmonary hypertension. Acetylcholine r laxes pre- 
constricted vascular smooth muscle by binding to 
muscarinic receptors on the endothelial cell, causing 
the release of a potent vasodilating substance called 
endothelium-derived r laxing factor. 16 In 1987, ni- 
tric oxide was reported to be an important endothe- 
lium-derived relaxing factor. 3Nitric oxide is thought 
to diffuse from the endothelium toadjacent smooth 
muscle and produce relaxation through a cyclic 
guanosine monophosphate-dependent pathway. 
The vascular esponse to acetylcholine is altered in 
a number of conditions, uch as chronic obstructive 
lung disease, 17 pulmonary hypertension after cardio- 
pulmonary bypass, Is and lung transplantation 19'2° 
wherein significant endothelial nitric oxide produc- 
tion is inadequate. However, vasodilatation may be 
elicited by inhaled nitric oxide, an endothelium- 
independent smooth muscle relaxant. 
We previously tested the effects of short periods 
of nitric oxide inhalation (40 to 60 ppm) and sys- 
temic prostaglandin E 1 (0.03 to 0.06 mg/kg per 
minute) on hemodynamics and arterial oxygenation 
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Table III. Effect of nitric oxide on hemodynamics and arterial blood gas 
Baseline One hour Two hours Four hours Eight hours 
Pao2/Fioz 88 -+ 10 153 _+ 30* 153 + 27* 175 -+ 32* 188 _+ 25? 
Pacoz (ram Hg) 48 _+ 3 47 _+ 4 42 + 2 41 _+ 2 41 _+ 2 
mAP (ram Hg) 75 _+ 4 77 _+ 2 74 + 2 78 _+ 3 70 _+ 2 
mPAP (ram Hg) 30 _+ 2 26 _+ 2* 26 + 2* 27 _+ 2* 26 _+ 1" 
mPCWP (mm Hg) 15 _+ 2 14 _+ 2 14 + 2 13 _+ 2 13 _+ 2 
mCVP (mm Hg) 10 _+ 1 10 -+ 1 9 -- 1 8 _+ 1 9 _+ 1 
CI (L/min/m 2) 2.9 _+ 0.2 2.6 _+ 0.2 2.4 ,+ 0.1 2.5 _+ 0.2 2.6 + 0.2 
mAP, Mean arterial pressure; mPAP, mean pulmonary artery pressure; mPCWP, mean pulmonary capillary wedge pressure; mCVP, mean central venous 
pressure; C/, cardiac index. Data were obtained from 13 patients treated with inhaled nitric oxide excluding two patients who required ECMO immediately 
after transplantation, mPCWP was obtained from only nine patients. 
*p < 0.05 versus baseline value. 
tp < 0.01 versus baseline value. 
in patients after bilateral ung transplantation. 5 In 
patients with impaired oxygenation, nitric oxide 
improved PaoJFio2 ratio and lowered mean pulmo- 
nary artery pressure without systemic circulatory 
effects. In contrast, prostaglandin E 1 did not im- 
prove oxygenation and lowered systemic arterial 
pressure. Interestingly, in patients without impaired 
oxygenation, nitric oxide was of no benefit and 
paradoxically worsened oxygenation. We have also 
demonstrated the beneficial effects of inhaled 
nitric oxide on allograft dysfunction owing to 
reperfusion injury in a canine single lung trans- 
plant model. 6
On the basis of this experience and several reports 
on nitric oxide treatment for pulmonary hyperten- 
sion 21-23 and adult respiratory distress syndrome, 4 
extended inhaled nitric oxide treatment has been 
given to the 15 lung transplant recipients with severe 
allograft dysfunction since February 1993. Inhaled 
nitric oxide rapidly improved oxygenation and de- 
creased pulmonary artery pressure without systemic 
circulatory effects. It should also be noted that 
inhaled nitric oxide does not cause tachyphylaxis. 
Because nitric oxide, an endothelium-independent 
smooth muscle relaxant, is delivered via the airway, 
pulmonary blood flow is redistributed away from 
nonventilated regions of the lungs and toward ven- 
tilated regions, thereby improving the matching of 
ventilation and perfusion. Another beneficial effect 
may be derived from a potential antineutrophil 
effect of nitric oxide. Our previous canine study 
demonstrated that preserved lung allografts treated 
with inhaled nitric oxide had decreased myeloper- 
oxidase activity, indicating decreased neutrophil se- 
questration in comparison with that of untreated 
allografts. 
Patients with severe lung allograft dysfunction 
usually require prolonged mechanical ventilation. 
We 24 have recently reported that prolonged me- 
chanical ventilation is associated with an increased 
incidence of airway complications. Whether this 
increase is due to mechanical ventilation itself or to 
the parenchymal injury necessitating mechanical 
ventilation is not known. Our observations suggest 
that inhaled nitric oxide may shorten the time 
required for mechanical ventilation in patients with 
severe allograft dysfunction. Interestingly, four pa- 
tients treated without nitric oxide had airway com- 
plications, two of which proved fatal. In contrast, no 
airway complications were noted when nitric oxide 
was used. 
ECMO has been used when conventional mea- 
sures for treatment of severe allograft dysfunction 
proved unsuccessfulY In our entire experience of 
243 patients undergoing lung transplantation, only 
six patients required ECMO. Four of them survived 
and were discharged from the hospital. We have 
avoided the use of ECMO as much as possible 
because of the potential complications of bleeding, 
infection, and renal insufficiency. We speculate that 
at least two more patients would have required 
ECMO had nitric oxide not been available. On the 
other hand, one patient required ECMO 24 hours 
after transplantation because of progressive al- 
lograft dysfunction despite nitric oxide therapy. This 
patient's lung never recovered. Our current strategy 
is to use nitric oxide as the first therapeutic inter- 
vention in the presence of severe allograft dysfunc- 
tion and to reserve ECMO for subsequent treatment 
failures or for circumstances in which euvolemic 
hemodynamic nstability proves refractory to man- 
agement with standard pressor and inotropic agents. 
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The absence of systemic vasodilatation with in- 
haled nitric oxide was confirmed in this study. The 
lack of systemic effects results from the rapid inac- 
tivation of nitric oxide by hemoglobin in red blood 
cells. 18 The reaction of hemoglobin and nitric oxide 
forms nitrosyl hemoglobin and subsequently methe- 
moglobin. 26 Intravenously infused vasodilators uch 
as prostaglandin El, on the other hand, cause both 
pulmonary and systemic vasodilatation. 5'15 The 
dose of a vasodilator agent is limited by concomitant 
dilatation of the systemic vasculature, leading to 
systemic arterial hypotension. 
The therapeutic importance of our data on in- 
haled nitric oxide is evident but must be considered 
in conjunction with possible toxic effects. Nitric 
oxide can be converted by oxidation to nitric dioxide 
and other toxic agents such as peroxynitrite, result- 
ing in lung injury. 27 Formation of methemoglobin 
may decrease oxygen delivery. There is indirect 
evidence that nitric oxide may be directly related to 
allograft rejection. In a rat left lung allograft model 
we 28 have recently demonstrated that inhibition of 
nitric oxide synthase by aminoguanidine markedly 
delayed the onset and decreased the severity of lung 
allograft rejection. Little evidence for nitric oxide 
toxicity exists with exposures less than 100 ppm in 
normal rats 27 and rabbits. 29 In fact, in our experi- 
ence we observe no complications associated with 
extended nitric oxide inhalation for up to 217 hours. 
Transient mild methemoglobinemia occurred in two 
patients and was successfully treated with ascorbic 
acid administration. We did not encounter any 
episodes of intractable acute rejection. 
In summary, this study demonstrates that inhaled 
nitric oxide improves gas exchange and decreases 
pulmonary artery pressure in patients with early 
allograft dysfunction. It also suggests that inhaled 
nitric oxide may shorten postoperative mechanical 
ventilation time, reduce airway complications, and 
reduce mortality in patients with severe lung al- 
lograft dysfunction. 
We acknowledge the assistance of Mary Ann Kelly in 
preparation of the manuscript and statistical advice from 
Richard B. Schuessler, PhD. 
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Discussion 
Dr. Paul F. Waters (Los Angeles, Calif.). We in our 
program have also encountered severe arly graft dysfunc- 
tion that leaves us helplessly watching the patient become 
hypoxemic and hypotensive, with very few therapeutic 
modalities other than ECMO. We have seen an excellent 
therapeutic response to nitric oxide in some cases and 
have found it to be ineffective in others. Have any of your 
patients been unresponsive to nitric oxide therapy? 
Dr. Date. We had one patient who did not respond to 
nitric oxide treatment. This patient required ECMO 24 
hours after the initiation of nitric oxide, but the lung never 
recovered. This patient probably should have been treated 
with ECMO earlier. However, we do not know how to 
distinguish between patients who should be treated with 
ECMO from the beginning and those who should be 
treated with nitric oxide when the graft dysfunction isvery 
severe .  
Dr. Waters. Is your use of nitric oxide now still a 
reactive process or are you using it prophylactically in 
patients in whom the risk is particularly high, for instance, 
patients with Eisenmenger-type ulmonary vascular dis- 
ease or those with primary pulmonary hypertension? 
Dr. Date. We have actually tested more than 50 patients 
with a short course of nitric oxide. Only the patients with 
graft dysfunction as manifested by Pao2/Fio 2 ratios less 
than 150 responded well, which means oxygenation was 
improved. However, nitric oxide had an adverse ffect in 
patients who did not have graft dysfunction, which means 
oxygenation became worse. Therefore, we use nitric oxide 
only for the patient with graft dysfunction as manifested 
by a Pao2/Fi% ratio less than 150. 
Dr. Waters. I see. I noticed that some of your patients 
with pulmonary vascular disease had single lung trans- 
plants and some had double lung transplants. What were 
the particular reasons why one patient would receive one 
operation and another the other? 
Dr. Date. Currently, if both lungs are available, we use 
bilateral lung transplantation for this group of patients. 
However, donor shortage is a big problem. If single lung 
transplantation is the only option for that patient, then we 
use that option. However, the primary choice for us is 
double lung transplantation at this time. 
Dr. Waters. Are you saying that there is no particular 
stratification, that the type of treatment depends on 
whether there is a double lung block available? 
Dr. Date. The quality of the lung also has an impact. If 
we do a single lung transplantation, the lung has to be 
perfect and the lung has to be close to the center. The 
ischemic time should be shorter than for bilateral ung 
transplantation, because the patient who receives a single 
lung transplant for pulmonary hypertension has a difficult 
course. 
Dr. Waters. My final question relates to any thoughts 
that you might have on the etiology of this severe graft 
dysfunction. Do you think it is an immunologic process, a
reperfusion injury, a combination? 
Dr. Date. We have investigated the effect of nitric oxide 
using a canine left single lung transplant model, and we 
found that by administering nitric oxide we could reduce 
myeloperoxidase activity. Therefore, maybe one of the 
causes of this reimplantation phenomenon is neutrophil 
activation, and nitric oxide may be working on this phenom- 
enon. 
Dr. Waters. Have you used leukocyte depletion at all in 
reperfusion? 
Dr. Date. No, not yet. 
Dr. Robert C. Rohhins (Stanford, Calif.). I agree with 
Dr. Waters' comments about primary pulmonary hyper- 
tension and your comments about the use of double lung 
transplantation. I think that is the best operation. 
In patients with primary pulmonary hypertension, have 
you observed that if you do the operations without cardio- 
pulmonary bypass dysfunction is worse in the lung that is 
implanted first, probably related to reperfusion i jury? 
Dr. Date. We have to use cardiopulmonary b pass for 
transplant operations in patients with pulmonary hyper- 
tension. If we do not, the patient cannot tolerate the 
pneumonectomy. Therefore, we electively use cardiopul- 
monary bypass for all patients with pulmonary hyperten- 
sion. With regard to bilateral lung transplantation in this 
group of patients, function in the first transplanted lung is 
usually poorer than that of the second transplanted lung, 
even though the second lung has a longer ischemic time. 
The probable reason is hyperperfusion to the first trans- 
planted lung during the second lung implantation, as you 
mentioned. 
